GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Retained Earnings

Biomarin Pharmaceutical (MIL:1BMRN) Retained Earnings : €-288 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biomarin Pharmaceutical's retained earnings for the quarter that ended in Sep. 2024 was €-288 Mil.

Biomarin Pharmaceutical's quarterly retained earnings increased from Mar. 2024 (€-490 Mil) to Jun. 2024 (€-395 Mil) and increased from Jun. 2024 (€-395 Mil) to Sep. 2024 (€-288 Mil).

Biomarin Pharmaceutical's annual retained earnings increased from Dec. 2021 (€-824 Mil) to Dec. 2022 (€-745 Mil) and increased from Dec. 2022 (€-745 Mil) to Dec. 2023 (€-570 Mil).


Biomarin Pharmaceutical Retained Earnings Historical Data

The historical data trend for Biomarin Pharmaceutical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Retained Earnings Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,548.64 -708.24 -823.72 -745.00 -569.97

Biomarin Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -601.49 -569.97 -490.26 -395.49 -287.99

Biomarin Pharmaceutical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Biomarin Pharmaceutical  (MIL:1BMRN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Biomarin Pharmaceutical Headlines

No Headlines